Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $37.59M fell 8.4% year over year, behind the +26.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at +75.5% a year.

Context

  • Selling, general & admin amounted to 104.3% of revenue in FY2025, down 406.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $522.17M (+190.6%) for the fiscal year ending Dec 2026, a step up from the +48.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.59M-24.7% QoQ
Last fiscal yearDec 2025
$179.68M+48.6% YoY
LTMMar 2026
$176.24M+26.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.4%+201.8%+210.2 pp
1 year+48.6%+190.6%+142.0 pp
3-year CAGR+75.5%+80.3%+4.8 pp
5-year CAGR+58.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
179.68M USD
Year-over-year change
+48.6%
4-year CAGR
+63.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's LTM Mar 2026 selling, general & admin of $176.24M is the 2nd highest of the 11 companies compared; the peer median is $67.47M.
  • Its year-over-year change of +26.9% is the 4th highest of 10, against a peer median of +5.1%.
  • Selling, general & admin amounts to 81.2% of revenue for SNDX, versus a peer median of 87.5%.
SNDX Competitors Peer median
Selling, General & Admin for SNDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$15.14B +24248.6%-5.7%5694.1%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$176.24M +26.9%+75.5%81.2%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M +32.6%+68.1%93.3%
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M -7.8%+1.9%90.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M +57.0%+11.6%11.1%
REPLReplimune Group, Inc.LTM Dec 2025$69.65M ———
XNCRXencor, Inc.LTM Jun 2026$65.29M +5.1%+10.3%62.2%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M -27.9%-12.7%24.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$31.1M -1.0%-11.4%87.5%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M -23.4%-6.3%—
Peer median (excluding SNDX) $67.47M+5.1%+1.9%87.5%

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.71M0023.68M172.35M
Cost of Revenue000826K6.97M
Gross Profit139.71M0022.85M165.38M
Gross Margin100.0%——96.5%96.0%
Research & Development88.25M118.5M163.03M241.65M258.78M
Selling, General & Admin25.24M33.26M66.92M120.88M179.68M
Operating Expenses113.49M151.76M229.95M362.53M438.47M
Depreciation & Amortization43K33K12K8K6K
EBITDA26.87M(146.17M)(209.14M)(313.82M)(251.63M)
EBITDA Margin19.2%——-1325.3%-146.0%
Operating Income26.22M(151.76M)(229.95M)(339.67M)(273.08M)
Operating Margin18.8%——-1434.4%-158.4%
Interest Income403K5.87M21.16M26.09M22.73M
Interest Expense1.9M3.14M208K4.93M33.79M
Other Income / Expenses(1.29M)2.42M20.59M20.91M(12.34M)
Income Before Tax24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Pre-Tax Margin17.8%——-1346.1%-165.6%
Income Tax Expense00000
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Net Margin17.8%——-1346.1%-165.6%
EPS (Basic)0.48(2.46)(2.98)(3.73)(3.29)
EPS (Diluted)0.48(2.46)(2.98)(3.73)(3.29)
Weighted Avg Shares52.06M60.76M70.37M85.62M86.63M
Weighted Avg Shares (Diluted)52.06M60.76M70.37M85.62M86.63M

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.